Review



mouse recombinant 5 gdf9  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems mouse recombinant 5 gdf9
    Mouse Recombinant 5 Gdf9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf9/Recombinant+Mouse+GDF-9+Protein/pm41688648-142-51-60
    Average 94 stars, based on 27 article reviews
    mouse recombinant 5 gdf9 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Growth Differentiation Factor 9 (GDF9) Forms an Incoherent Feed-forward Loop Modulating Follicle-stimulating Hormone β-Subunit (FSHβ) Gene Expression
    Article Snippet: .. Materials Reagents were obtained from the following sources: GnRH, Bachem (Torrance, CA); cholera toxin (CTX), Calbiochem; ERK inhibitor U0126, JNK inhibitor SP600125, p38 inhibitor SB203580, Src inhibitor PP2, and PKA inhibitor H-89, Calbiochem; GDF9, ALK5, Smad2/3, and inhibin α siRNAs, Dharmacon (On-Target plus siRNA SMARTpool, Denver, CO); GDF9, R&D Systems; actinomycin D, Sigma; anti-GDF9 (c-18) and GAPDH antibodies, Santa Cruz Biotechnology; anti-Smad2/3 and anti-phospho-Smad2/3 antibodies, Cell Signaling Technology; anti-GDF9 antibody used in immunoneutralization experiments, Biorbyt (Cambridge, UK); activin A human recombinant, VWR (Lutterworth, UK); SB-505124, Tocris Bioscience (Bristol, UK). ..

    Article Title: The Bone Morphogenetic Protein 15 Up-Regulates the Anti-Müllerian Hormone Receptor Expression in Granulosa Cells.
    Article Snippet: Collection and culture of hGCs After oocyte isolation, follicular fluids from each patient were centrifuged as described (27) through a Percoll gradient at 350g for 15 minutes. hGCs were collected at the interface and seeded at 3 105 cells per well in 6-well plates in DMEM/F-12 containing 10% fetal calf serum, 100-U/mL penicillin, and 100- g/mL streptomycin (all products from Invitrogen). .. The next day, hGCs were treated for 48 hours in serum-free conditions with or without 10 ng/mL of recombinant human (rh)BMP4, BMP15, and/or GDF9 (R&D Systems Europe). ..

    Article Title: Growth Differentiation Factor 9 (GDF9) Forms an Incoherent Feed-forward Loop Modulating Follicle-stimulating Hormone β-Subunit (FSHβ) Gene Expression
    Article Snippet: .. Reagents were obtained from the following sources: GnRH, Bachem (Torrance, CA); cholera toxin (CTX), Calbiochem; ERK inhibitor U0126, JNK inhibitor SP600125, p38 inhibitor SB203580, Src inhibitor PP2, and PKA inhibitor H-89, Calbiochem; GDF9, ALK5, Smad2/3, and inhibin α siRNAs, Dharmacon (On-Target plus siRNA SMARTpool, Denver, CO); GDF9, R&D Systems; actinomycin D, Sigma; anti-GDF9 (c-18) and GAPDH antibodies, Santa Cruz Biotechnology; anti-Smad2/3 and anti-phospho-Smad2/3 antibodies, Cell Signaling Technology; anti-GDF9 antibody used in immunoneutralization experiments, Biorbyt (Cambridge, UK); activin A human recombinant, VWR (Lutterworth, UK); SB-505124, Tocris Bioscience (Bristol, UK). ..

    Incubation:

    Article Title: Prediction of ovarian aging using ovarian expression of BMP15, GDF9, and C-KIT
    Article Snippet: .. The sections were incubated with antiserum at a dilution of 1:200 in BMP15 (ORB247897, Biorbyt, Cambridge, UK), 1: 100 in GDF9 (AF739, R&D Systems, MN, USA), and 1:100 in C-KIT ( {"type":"entrez-protein","attrs":{"text":"ORB10286","term_id":"1177131250","term_text":"ORB10286"}} ORB10286 , Biorbyt) for overnight. ..

    other:

    Article Title: Identification of apelin/APJ signaling dysregulation in a human iPSC-derived granulosa cell model of Turner syndrome.
    Article Snippet: This medium was refreshed every 48 h until day 7, at which point the medium was replaced with maturation medium containing EB basal medium supplemented with small molecules and proteins based on each condition: condition #1: 10 ng/mL BMP4, 5 ng/mL bFGF, and follistatin 288 (R&D, 5836-FS-0251/CF); condition #2 and condition #4: 5 ng/mL BMP4, 10 μM SB4, 5 ng/mL bFGF, and follistatin 288; condition #3: 10 ng/mL BMP4, 1 μg/mL heparin (Sigma-Aldrich, H3149), 50 ng/mL GDF9 (R&D Systems, 8266-G9-010/CF), and 25 ng/mL BMP15 (R&D Systems, 5096-BM005).



    Similar Products

    93
    Bioss rabbit polyclonal gdf9 antibody
    Rabbit Polyclonal Gdf9 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf9/SCF+Polyclonal+Antibody/pm42009647-415-0-12
    Average 93 stars, based on 1 article reviews
    rabbit polyclonal gdf9 antibody - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology gdf9
    Real-time RT-PCR oligonucleotide primer sequences and cycling conditions
    Gdf9, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf9/GDF9+Rabbit+pAb/pmc13518760-93-14-12
    Average 94 stars, based on 1 article reviews
    gdf9 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology anti gdf9
    Real-time RT-PCR oligonucleotide primer sequences and cycling conditions
    Anti Gdf9, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf9/GDF9+Rabbit+pAb/pmc13203260-126-24-39
    Average 94 stars, based on 1 article reviews
    anti gdf9 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology a2739
    Real-time RT-PCR oligonucleotide primer sequences and cycling conditions
    A2739, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf9/GDF9+Rabbit+pAb/pmc13270137-47-5-3
    Average 94 stars, based on 1 article reviews
    a2739 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    86
    Jackson Laboratory gdf9 cre
    Real-time RT-PCR oligonucleotide primer sequences and cycling conditions
    Gdf9 Cre, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf9/cre+gdf9/bio_rxiv__64898__2026__03__30__715371-226-10-17
    Average 86 stars, based on 1 article reviews
    gdf9 cre - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    94
    Cyagen Biosciences gdf9 cre mice
    Real-time RT-PCR oligonucleotide primer sequences and cycling conditions
    Gdf9 Cre Mice, supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf9/Gdf9/pm41740685-74-5-10
    Average 94 stars, based on 1 article reviews
    gdf9 cre mice - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    R&D Systems mouse recombinant 5 gdf9
    Real-time RT-PCR oligonucleotide primer sequences and cycling conditions
    Mouse Recombinant 5 Gdf9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf9/Recombinant+Mouse+GDF-9+Protein/pm41688648-142-51-60
    Average 94 stars, based on 1 article reviews
    mouse recombinant 5 gdf9 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    R&D Systems mouse recombinant gdf9
    Effects of oocyte-secreted factors on secondary follicles cultured in 0.1 % alginate bead with viscosity 4-12 cP. A; The effect of oocyte-secreted factors on the development of secondary follicles with multilayered granulosa cells. Ten secondary follicles with multilayered granulosa cells were placed in each alginate bead and then were cultured for 7 days in culture medium containing 10 ng/ml ovine FSH, <t>GDF9</t> (0, 10 and 100 ng/ml) and ITS Supplement in the presence of 1 % (v/v) FBS. The diameter of each secondary follicle was measured 7 days after culture. In the box plot: bar, × = median, box = 25 th to 75 th percentiles, whiskers = 10 th and 90 th percentile. N=3 animals for each treatment. The experiment was repeated three times. The different symbols represent significant differences (p < 0.05). *; Significant differences observed between days 0 and 7 in the 10 and 100 ng/mL GDF9 groups (p < 0.05). B; The effect of oocyte-secreted factors on the expression of marker genes about the follicular development, luteinization and inflammation/anti-inflammatory in granulosa cells of cultured secondary follicles. Ten secondary follicles with multilayered granulosa cells were placed in each alginate bead and then were cultured for 7 days in culture medium containing 10 ng/ml ovine FSH, GDF9 (0, 10 and 100 ng/ml) and ITS Supplement in the presence of 1 % (v/v) FBS. The diameter of each secondary follicle was measured 7 days after culture. Levels of mRNA were normalized to that of L19 . The values are the mean ± SEM. N=3 animals for each treatment. The experiment was repeated three times. The value of 0 ng/ml GDF9 was set as 1, and the data are presented as fold induction. *Significant differences observed between the 0 ng/mL and 10 or 100 ng/mL GDF9 groups (p < 0.05).
    Mouse Recombinant Gdf9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf9/Recombinant+Mouse+GDF-9+Protein/pmc12982486-206-48-56
    Average 94 stars, based on 1 article reviews
    mouse recombinant gdf9 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    RayBiotech inc goe
    ( A ) Schematic illustration of the in vitro DO model; concentration of cisplatin, 2.7 μg/ml; <t>EV/GOE,</t> 1 × 10 6 particles/ml; time of treatment, 24 hours (h). ( B ) Flow cytometry analysis of GC viability, apoptosis, and cell death. ( C to E ) Quantification of flow cytometry data, showing the efficacy of EVs in treating DO in vitro. ( F ) No statistically significant difference in apoptosis rates between GOEs <t>and</t> <t>GDF-9</t> –overexpressing MSCs. n = 3, data are presented as means ± SD. This figure was created in part using BioRender.com . Created in BioRender. Zhang, S. (2025) https://BioRender.com/zv1tbzt . IC 50 , median inhibitory concentration. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.
    Goe, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf9/Human+GDF-9+ELISA/pmc12693986-187-9-17
    Average 93 stars, based on 1 article reviews
    goe - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    Image Search Results


    Real-time RT-PCR oligonucleotide primer sequences and cycling conditions

    Journal: Journal of Assisted Reproduction and Genetics

    Article Title: Novel anti-Mullerian hormone receptor 2 binding peptide prevents chemotherapy-related ovarian follicle loss in a mouse model

    doi: 10.1007/s10815-026-03902-5

    Figure Lengend Snippet: Real-time RT-PCR oligonucleotide primer sequences and cycling conditions

    Article Snippet: We measured colorimetric ELISA for FSH-R (Bioassay technology laboratory), Ki67 (MYBioSource), BMP15 (ABclonal Technology), GDF9 (Elabscience), SMAD 5 and SMAD 8/9 (MYBioSource; SMAD 5, MBS9714237, and SMAD 8/9, MBS9714235), following the manufacturer protocol.

    Techniques: Quantitative RT-PCR, Amplification

    The effect of AMHR2BP on ovarian cortex. Follicle measurements in C57BL/6 J female mice at baseline (12 weeks old, white), or after treatment with AMHR2BP (blue), rAMH (green), or placebo (PBS, black) for 3 weeks. A Primordial follicles (PDF). B Primary follicles (PRF). C Secondary follicles (SEF). D Tertiary follicles (TRF). E Corpora lutea. Log2 fold change of real-time RT-PCR ovarian cortex tissue expression of F inhibin B, as well as G BMP15, Caspase 3 (Cas-3), FSH-R2, GDF9, and Ki67, in the AMHR2BP, rAMH, and placebo (PBS) groups compared to the baseline group. H Log2 fold change of ovarian tissue protein concentrations of BMP15, Caspase 3, FSH-R2, GDF9, and Ki67 in C57BL/6 J female mice at baseline (12 weeks old), or after treatment with AMHR2BP, rAMH, or placebo (PBS) for 3 weeks. Both treatment regimens exhibited a significant decrease in concentration of all parameters, showing inhibition of cellular function. The asterisks indicate significance of the comparisons between the different treatments using Kruskal–Wallis test for comparison of medians (* p < 0.05; ** p < 0.005)

    Journal: Journal of Assisted Reproduction and Genetics

    Article Title: Novel anti-Mullerian hormone receptor 2 binding peptide prevents chemotherapy-related ovarian follicle loss in a mouse model

    doi: 10.1007/s10815-026-03902-5

    Figure Lengend Snippet: The effect of AMHR2BP on ovarian cortex. Follicle measurements in C57BL/6 J female mice at baseline (12 weeks old, white), or after treatment with AMHR2BP (blue), rAMH (green), or placebo (PBS, black) for 3 weeks. A Primordial follicles (PDF). B Primary follicles (PRF). C Secondary follicles (SEF). D Tertiary follicles (TRF). E Corpora lutea. Log2 fold change of real-time RT-PCR ovarian cortex tissue expression of F inhibin B, as well as G BMP15, Caspase 3 (Cas-3), FSH-R2, GDF9, and Ki67, in the AMHR2BP, rAMH, and placebo (PBS) groups compared to the baseline group. H Log2 fold change of ovarian tissue protein concentrations of BMP15, Caspase 3, FSH-R2, GDF9, and Ki67 in C57BL/6 J female mice at baseline (12 weeks old), or after treatment with AMHR2BP, rAMH, or placebo (PBS) for 3 weeks. Both treatment regimens exhibited a significant decrease in concentration of all parameters, showing inhibition of cellular function. The asterisks indicate significance of the comparisons between the different treatments using Kruskal–Wallis test for comparison of medians (* p < 0.05; ** p < 0.005)

    Article Snippet: We measured colorimetric ELISA for FSH-R (Bioassay technology laboratory), Ki67 (MYBioSource), BMP15 (ABclonal Technology), GDF9 (Elabscience), SMAD 5 and SMAD 8/9 (MYBioSource; SMAD 5, MBS9714237, and SMAD 8/9, MBS9714235), following the manufacturer protocol.

    Techniques: Quantitative RT-PCR, Expressing, Concentration Assay, Inhibition, Cell Function Assay, Comparison

    Effects of oocyte-secreted factors on secondary follicles cultured in 0.1 % alginate bead with viscosity 4-12 cP. A; The effect of oocyte-secreted factors on the development of secondary follicles with multilayered granulosa cells. Ten secondary follicles with multilayered granulosa cells were placed in each alginate bead and then were cultured for 7 days in culture medium containing 10 ng/ml ovine FSH, GDF9 (0, 10 and 100 ng/ml) and ITS Supplement in the presence of 1 % (v/v) FBS. The diameter of each secondary follicle was measured 7 days after culture. In the box plot: bar, × = median, box = 25 th to 75 th percentiles, whiskers = 10 th and 90 th percentile. N=3 animals for each treatment. The experiment was repeated three times. The different symbols represent significant differences (p < 0.05). *; Significant differences observed between days 0 and 7 in the 10 and 100 ng/mL GDF9 groups (p < 0.05). B; The effect of oocyte-secreted factors on the expression of marker genes about the follicular development, luteinization and inflammation/anti-inflammatory in granulosa cells of cultured secondary follicles. Ten secondary follicles with multilayered granulosa cells were placed in each alginate bead and then were cultured for 7 days in culture medium containing 10 ng/ml ovine FSH, GDF9 (0, 10 and 100 ng/ml) and ITS Supplement in the presence of 1 % (v/v) FBS. The diameter of each secondary follicle was measured 7 days after culture. Levels of mRNA were normalized to that of L19 . The values are the mean ± SEM. N=3 animals for each treatment. The experiment was repeated three times. The value of 0 ng/ml GDF9 was set as 1, and the data are presented as fold induction. *Significant differences observed between the 0 ng/mL and 10 or 100 ng/mL GDF9 groups (p < 0.05).

    Journal: Scientific Reports

    Article Title: Changes in ovarian hardness and elasticity affect the development and function of secondary follicles

    doi: 10.1038/s41598-026-39396-5

    Figure Lengend Snippet: Effects of oocyte-secreted factors on secondary follicles cultured in 0.1 % alginate bead with viscosity 4-12 cP. A; The effect of oocyte-secreted factors on the development of secondary follicles with multilayered granulosa cells. Ten secondary follicles with multilayered granulosa cells were placed in each alginate bead and then were cultured for 7 days in culture medium containing 10 ng/ml ovine FSH, GDF9 (0, 10 and 100 ng/ml) and ITS Supplement in the presence of 1 % (v/v) FBS. The diameter of each secondary follicle was measured 7 days after culture. In the box plot: bar, × = median, box = 25 th to 75 th percentiles, whiskers = 10 th and 90 th percentile. N=3 animals for each treatment. The experiment was repeated three times. The different symbols represent significant differences (p < 0.05). *; Significant differences observed between days 0 and 7 in the 10 and 100 ng/mL GDF9 groups (p < 0.05). B; The effect of oocyte-secreted factors on the expression of marker genes about the follicular development, luteinization and inflammation/anti-inflammatory in granulosa cells of cultured secondary follicles. Ten secondary follicles with multilayered granulosa cells were placed in each alginate bead and then were cultured for 7 days in culture medium containing 10 ng/ml ovine FSH, GDF9 (0, 10 and 100 ng/ml) and ITS Supplement in the presence of 1 % (v/v) FBS. The diameter of each secondary follicle was measured 7 days after culture. Levels of mRNA were normalized to that of L19 . The values are the mean ± SEM. N=3 animals for each treatment. The experiment was repeated three times. The value of 0 ng/ml GDF9 was set as 1, and the data are presented as fold induction. *Significant differences observed between the 0 ng/mL and 10 or 100 ng/mL GDF9 groups (p < 0.05).

    Article Snippet: Ten of secondary follicles were placed in one alginate bead and were cultured for 7 days in the medium (DMEM/F12 containing penicillin and streptomycin) containing 10 ng/ml ovine FSH (NIDDK, Torrance, CA, USA) and ITS Supplement (Sigma) in the presence of 1 % (v/v) FBS with or without mouse recombinant GDF9 (0, 10 and 100 ng/ml) (R&D Systems Inc., Minneapolis, MN) or Cytochalasin (0, 1 and 10 μM) (Sigma) at 37 °C and 5% CO 2 condition.

    Techniques: Cell Culture, Viscosity, Expressing, Marker

    ( A ) Schematic illustration of the in vitro DO model; concentration of cisplatin, 2.7 μg/ml; EV/GOE, 1 × 10 6 particles/ml; time of treatment, 24 hours (h). ( B ) Flow cytometry analysis of GC viability, apoptosis, and cell death. ( C to E ) Quantification of flow cytometry data, showing the efficacy of EVs in treating DO in vitro. ( F ) No statistically significant difference in apoptosis rates between GOEs and GDF-9 –overexpressing MSCs. n = 3, data are presented as means ± SD. This figure was created in part using BioRender.com . Created in BioRender. Zhang, S. (2025) https://BioRender.com/zv1tbzt . IC 50 , median inhibitory concentration. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.

    Journal: Science Advances

    Article Title: Repair of female reproductive function by GDF-9–overexpressing extracellular vesicles via ACVR1B/SMAD2 regulation in ovarian granulosa

    doi: 10.1126/sciadv.adw9006

    Figure Lengend Snippet: ( A ) Schematic illustration of the in vitro DO model; concentration of cisplatin, 2.7 μg/ml; EV/GOE, 1 × 10 6 particles/ml; time of treatment, 24 hours (h). ( B ) Flow cytometry analysis of GC viability, apoptosis, and cell death. ( C to E ) Quantification of flow cytometry data, showing the efficacy of EVs in treating DO in vitro. ( F ) No statistically significant difference in apoptosis rates between GOEs and GDF-9 –overexpressing MSCs. n = 3, data are presented as means ± SD. This figure was created in part using BioRender.com . Created in BioRender. Zhang, S. (2025) https://BioRender.com/zv1tbzt . IC 50 , median inhibitory concentration. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.

    Article Snippet: The protein concentration of GDF-9 in control EVs and GOE was quantitatively analyzed using the ELISA kit (Raybiotech, ELH-GDF9-1).

    Techniques: In Vitro, Concentration Assay, Flow Cytometry